This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: H35.58 | Special Copayment Reduction: V209 | Coverage period: 5 years |
| B. Synonyms | Stargardt macular dystrophy, STGD1, Fundus flavimaculatus, ABCA4 retinopathy, juvenile macular dystrophy |
| C. Adult onset | Low to moderate likelihood of first presenting in adulthood — typical age of onset is the 10s to 30s; an adult form (mild ABCA4 variants) exists, and onset after age 45 has also been reported |
| 1. History | First described by Karl Stargardt in 1909; ABCA4 gene identified in the late 20th century |
| 2. Causes | ABCA4 gene variants → accumulation of toxic bisretinoids (A2E) in the retinal pigment epithelium (RPE) → photoreceptor degeneration |
| 3. Genetics | Autosomal recessive; ABCA4 gene (1p22.1); more than 1,200 pathogenic variants reported |
| 4. Epidemiology | Prevalence about 1/8,000–10,000; the most common juvenile macular dystrophy |
| 5. Pathophysiology | Loss of ABCA4 function → accumulation of 11-cis-retinal → A2E formation → oxidative stress → death of RPE and photoreceptor cells |
| 6. Symptoms | Progressive loss of central vision, color vision abnormality, delayed dark adaptation; late-stage visual acuity around 20/200 |
| 7. Signs | Macular atrophic lesions, yellow-white flecks at the RPE level, dark choroid (FAG), hypofluorescent macular lesions (FAF) |
| 8. Screening | FAF and visual acuity testing in children and adolescents with a family history; genetic testing (ABCA4 panel) |
| 9. Diagnosis | Definitive diagnosis by clinical findings + FAF + OCT + whole-genome/panel genetic testing; fluorescein angiography used in combination |
| 10. Treatment | No currently approved treatment; tinlarebant and gildeuretinol clinical trials ongoing; low vision rehabilitation |
| 11. Prognosis | Slowly progressive; final visual acuity of 20/200 or worse is common; peripheral visual field relatively preserved |
| 12. Prevention | UV protection; minimize exposure to bright light; high-dose vitamin A is contraindicated; genetic counseling |
| References | 10 key references with PMIDs |
Stargardt disease (STGD1) was described in 1909 when the German ophthalmologist Karl Stargardt first reported seven patients who had lost vision at a young age. He observed findings of bilateral macular dystrophy characterized by macular atrophy and yellow spots in the periphery, and named it "juvenile macular dystrophy." For the following decades, the disease was diagnosed mainly on the basis of fundus findings and clinical course.
In 1963, Franceschetti separately classified a variant with more widely distributed yellow fundus flecks as "fundus flavimaculatus (FFM)," but later studies of the ABCA4 gene confirmed that Stargardt disease and FFM are different points on a phenotypic spectrum of the same gene. In 1997, Allikmets et al. identified the ABCA4 (ATP-binding cassette subfamily A member 4) gene, located on the short arm of chromosome 1, and the molecular genetic mechanism was revealed for the first time. ABCA4 is responsible for removing toxic retinoid byproducts in the phototransduction cycle of retinal photoreceptors, and it was found that loss of function of this gene causes accumulation of A2E, a type of lipofuscin, leading to degenerative changes in the RPE and photoreceptors.
Subsequently, advances in high-resolution fundus autofluorescence (FAF), optical coherence tomography (OCT) and next-generation sequencing (NGS) greatly improved diagnostic accuracy, and since the 2000s clinical trials of various therapeutic approaches such as gene therapy, stem cell therapy and small-molecule drugs have been under way. In 2024, the clinical trial results of tinlarebant (a retinol-binding protein 4 inhibitor) and gildeuretinol (deuterium-modified vitamin A) drew attention.
The cause of Stargardt disease is pathogenic variants in the ABCA4 gene. The ABCA4 gene encodes a flippase protein located in the disc membrane of retinal photoreceptors, and it moves toxic retinoid byproducts generated in the visual cycle, in particular the precursor of N-retinylidene-N-retinylethanolamine (A2E), from the luminal side of the photoreceptor disc toward the cytoplasm.
When ABCA4 protein function is lost, N-retinylidene-phosphatidylethanolamine (NRPE), an intermediate of the phototransduction cycle, accumulates in the photoreceptor disc membrane and polymerizes to form A2E, a toxic bisretinoid lipofuscin component. A2E interferes with lysosomal function in RPE cells and generates cytotoxic oxidized substances through photo-oxidation reactions, inducing death of RPE cells and, in a cascade, degeneration of the RPE-dependent photoreceptors (cones and rods).
Cones in the center of the macula are damaged first, causing loss of central vision, and as the disease progresses, peripheral rods may also be affected. Exposure to bright light is known to amplify the toxicity of A2E through photo-oxidation, so a role as an environmental factor is also recognized. Vitamin A supplements can increase the supply of substrate to the visual cycle and promote A2E production, so high-dose administration is contraindicated.
Stargardt disease (STGD1) follows an autosomal recessive mode of inheritance. The causative gene, ABCA4, is located on the short arm of chromosome 1 (1p22.1) and encodes a 6.8 kb mRNA composed of 50 exons. More than 1,200 pathogenic or presumed pathogenic variants have been reported to date, and many are missense variants that partially or completely abolish protein function.
The most common pathogenic variants include c.5882G>A (p.Gly1961Glu), c.3386G>A (p.Gly1129Glu), c.2588G>C (p.Gly863Ala), and the deep intronic variant c.4539+2028C>T (IVS30+1, etc.). Deep intronic variants may be missed by standard exon-based sequencing, so when the disease is clinically suspected but no variant is found on a standard panel, deep intronic variant analysis should be considered.
A considerable genotype–phenotype correlation exists. Patients carrying severe loss-of-function (null) variants in both alleles show a severe phenotype with early onset (before age 10), whereas patients with a mild missense variant in one allele may show an adult-type phenotype (late-onset STGD1, onset after age 45). In addition to the ABCA4 gene, subtypes exist such as STGD2 (ELOVL4, autosomal dominant), STGD3 (ELOVL4) and STGD4 (PROM1).
Stargardt disease is the most common juvenile macular dystrophy worldwide, with an estimated prevalence of about 1/8,000 to 1/10,000. It is estimated to affect about 30,000 people in the United States and more than 150,000 worldwide, and it has a relatively high frequency among rare inherited retinal diseases. There is no sex difference, and it occurs in all ethnic groups, although differences in the proportions of some ethnic-specific variants have been reported.
According to age at onset, it is divided into early-onset (before age 10), intermediate-onset (ages 11–45) and late-onset (after age 45) forms, and the typical age of onset is the 10s to 20s. The earlier the onset, the greater the severity of the ABCA4 variants and the faster the course tends to be. The risk of occurrence in siblings of an affected family is 25%, consistent with the autosomal recessive mode of inheritance. Carriers (heterozygotes) show a normal phenotype, although there are reports that mild retinal changes may appear in old age.
The carrier frequency of ABCA4 variants is estimated at about 1/50 to 1/100 in the general population, consistent with the prevalence and Hardy-Weinberg equilibrium. The incidence tends to increase in populations with consanguineous marriage. Several unique ABCA4 variants have also been reported in the Korean population.
The ABCA4 protein is an ATP-dependent reverse flippase located in the disc membrane of the photoreceptor outer segment, and it transports N-retinylidene-phosphatidylethanolamine (NRPE) and phosphatidylethanolamine (PE) generated after photoexcitation from the luminal side of the disc membrane toward the cytoplasm. When this process proceeds normally, NRPE is converted to oxidized retinol by cytoplasmic retinoid reductase and re-enters the visual cycle.
When ABCA4 function is lost, NRPE accumulates excessively in the lumen of the disc membrane, and two molecules of NRPE undergo a condensation reaction to form A2PE (diretinoid-pyridinium-PE). When the disc membrane is shed from the tip of the photoreceptor outer segment and phagocytosed by phagolysosomes of RPE cells, A2PE is hydrolyzed in the acidic environment and finally converted to A2E. A2E destabilizes the lysosomal membrane and inhibits lysosomal enzyme activity, interfering with phagocytosis by RPE cells, and at the same time generates singlet oxygen and reactive oxygen species (ROS) on exposure to blue light, causing oxidative cell damage.
When RPE cell function declines, the nutrient and oxygen supply to photoreceptors and the support function for outer segment renewal decrease, and degeneration proceeds sequentially starting from the cones of the macula. Because the cone density in the fovea of the macula is the highest, loss of central vision is evident from the early stage. As the area of RPE atrophy expands, peripheral rods are also affected, and in advanced cases impaired dark adaptation may occur.
The initial symptom of Stargardt disease is slowly progressive bilateral loss of central vision. Most patients complain of visual impairment when reading or doing fine work, and some feel more discomfort in dim environments than in bright ones. In the early stage of onset, visual acuity often stays at a normal level for a considerable time and then gradually declines.
Among color vision abnormalities, red-green color vision defects are relatively common, and color vision loss worsens as the disease progresses. A central scotoma is a characteristic finding confirmed on visual field testing and directly impairs daily functions such as reading and driving. Some patients complain of glare (photophobia) and experience impaired dark adaptation, with delayed recovery of vision after exposure to bright light.
The peripheral visual field is preserved for a relatively long time, so independent ambulation is often possible, but as the disease progresses the peripheral rods are also affected and night vision impairment may appear. The final corrected visual acuity usually reaches about 20/200, and it is common for patients to meet the criteria for legal blindness (best corrected visual acuity < 20/200). Eye movement abnormalities and systemic symptoms do not accompany the disease, which is important for differentiating it from syndromic retinal dystrophies.
Fundus findings vary according to the stage and the severity of the ABCA4 variants. In the early stage, only fine granular changes of the macula may be observed, but as the disease progresses, atrophic lesions in a "beaten bronze" or "bull's eye" pattern appear in the macula. A characteristic feature is that yellow or yellow-white flecks at the RPE level are scattered over the posterior pole, and in cases showing a fundus flavimaculatus pattern, these spots are widely distributed beyond the equator.
On fluorescein angiography (FAG), a "dark/silent choroid" phenomenon, in which choroidal fluorescence is blocked, is characteristically observed. This is because lipofuscin in the RPE blocks the background choroidal fluorescence, and it is a finding relatively specific to Stargardt disease. On fundus autofluorescence (FAF), the hypofluorescent macular lesion corresponds to the area of RPE atrophy, and hyperfluorescent flecks are scattered in the periphery.
On optical coherence tomography (OCT), loss of the outer retinal layers, in particular disruption of the inner segment/outer segment junction (IS/OS junction, or ellipsoid zone) and atrophy of the RPE layer, can be identified, and subtle IS/OS loss can be observed on OCT even before changes appear on FAF, which is useful for assessing the early stage. Full-field electroretinography (full-field ERG) is normal or mildly reduced in the early stage, and reduced macular response appears first on multifocal ERG (mf-ERG).
Screening for Stargardt disease is performed mainly in high-risk groups with a family history. Regular eye examinations (best corrected visual acuity, color vision testing, fundus examination) are recommended for children and adolescents whose parents are ABCA4 carriers. In clinically suspected cases, that is, when a child or adolescent has progressive bilateral loss of central vision of unknown cause, FAF and OCT should be performed at an early stage to evaluate for macular dystrophy.
Even without a family history, fundus examination and retinal imaging including FAF are performed when there is visual loss or color vision abnormality of unknown cause beginning in adolescence. ABCA4 gene panel or whole exome sequencing is actively performed when clinical findings are consistent with Stargardt disease but a definitive diagnosis is difficult, or for the purpose of genetic counseling.
Newborn screening is not currently recommended for Stargardt disease. However, as gene therapy clinical trials for ABCA4-related Stargardt disease proceed, the importance of early genetic diagnosis is increasing, and a system for early molecular genetic diagnosis is expected to be established in the future as part of eligibility assessment for gene therapy.
The diagnosis of Stargardt disease is made through comprehensive evaluation of clinical findings, functional tests, retinal imaging and molecular genetic testing. The diagnostic criteria are ① fundus findings of macular atrophy or flecks, ② hypofluorescent macular lesion and hyperfluorescent peripheral flecks on FAF, ③ dark choroid on FAG, ④ loss of the ellipsoid zone on OCT, and ⑤ identification of pathogenic variants in both alleles of the ABCA4 gene.
Molecular genetic testing is essential for definitive diagnosis, and NGS of an inherited retinal dystrophy panel that includes at least ABCA4 is recommended. When only one pathogenic variant is identified on the panel (single-allele patients), deep intronic variant analysis and RNA studies should additionally be considered. Whole-genome sequencing (WGS) provides the widest diagnostic coverage, including deep intronic variants and structural variants (copy number variation).
Full-field ERG is relatively normal in early Stargardt disease, but in advanced cases photoreceptor responses may be reduced, which is useful for assessing the severity of Stargardt disease and for differentiating it from retinitis pigmentosa and other conditions. Multifocal ERG (mfERG) is used for quantitative evaluation of macular dysfunction. Fluorescein angiography is used to confirm the dark choroid finding and to differentiate similar diseases.
At present there is no treatment for Stargardt disease approved by the FDA, EMA or the Ministry of Food and Drug Safety. The basic principles of treatment are lifestyle adjustment to slow the rate of disease progression and low vision rehabilitation. Exposure to strong ultraviolet light and blue light can amplify the toxicity of A2E through photo-oxidation, so wearing UV-blocking glasses is recommended. High-dose vitamin A palmitate supplementation can accelerate the accumulation of A2E precursors in the setting of loss of ABCA4 function and is contraindicated.
Therapeutic approaches in clinical trials include tinlarebant (LBS-008), a retinol-binding protein 4 (RBP4) inhibitor. In a phase 2 clinical trial, tinlarebant reduced serum RBP4 by 80%, suppressing the delivery of vitamin A to the retina, and tended to slow the rate of vision loss in adolescent Stargardt patients. Gildeuretinol (C20-D3-retinol), a deuterated vitamin A, acts by inhibiting the bisretinoid joining reaction, the rate-limiting step of A2E formation, and showed the potential to suppress disease progression in early Stargardt patients in the TEASE-3 clinical trial.
As a gene therapy approach, a phase 1/2 trial is under way of ACDN-01 (RNA exon editing–based; FDA Fast Track designation in 2024) delivered via an AAV vector. Stem cell therapy (retinal pigment epithelial cell transplantation) is also being explored but is still at the clinical trial stage. Low vision rehabilitation includes assistive devices such as magnifiers, electronic magnifiers and screen readers and visual impairment rehabilitation training, and it contributes substantively to improving quality of life.
In most cases, Stargardt disease shows slowly progressive bilateral loss of central vision, and the final visual acuity commonly reaches 20/200 or worse. The earlier the age of onset (early-onset form), the worse the prognosis tends to be, which correlates with the severity of the ABCA4 gene variants. In the early-onset form, the criteria for legal blindness may be met within several years of diagnosis.
The peripheral visual field is preserved for a relatively long time, so independent ambulation and some activities of daily living are often possible. However, activities requiring central vision, such as reading, face recognition and driving, are greatly restricted owing to decline in macular function. In some patients, vision remains stable for several decades after diagnosis and then undergoes sudden worsening.
At present there is no treatment that can cure the disease or permanently halt its progression, but promising results have been reported in multiple clinical trials, so a treatment to suppress disease progression or restore some function may be approved within the next 10 years. Regular retinal imaging follow-up and continued ophthalmologic follow-up for assessing eligibility for gene therapy clinical trials are recommended.
At present there is no way to prevent the genetic occurrence of Stargardt disease, but genetic counseling can help with family planning. For carrier couples (both being ABCA4 heterozygotes), preimplantation genetic testing (PGT) or prenatal genetic diagnosis can determine whether the fetus is affected.
As secondary preventive measures to slow disease progression, wearing glasses that block ultraviolet (UV-A, UV-B) and blue light every day is recommended. Avoiding exposure to strong direct sunlight can theoretically reduce the amplification of A2E toxicity by photo-oxidation. High-dose vitamin supplements containing vitamin A palmitate (especially products marketed for retinal health) are contraindicated in patients with Stargardt disease, and physicians must clearly inform patients of this.
Smoking adversely affects retinal blood flow and oxidative stress, so smoking cessation is recommended. A balanced diet (an antioxidant diet including lutein, zeaxanthin and omega-3) may contribute to general retinal health, but a specific effect in Stargardt disease has not yet been demonstrated. Comprehensive management should be provided, including regular eye examinations, education on the use of low vision aids and psychosocial support.